Chris joined Brandon Capital in 2012.
Before this Chris was a Business Development Manager with CSL, Australia’s largest pharmaceutical company. At CSL Chris was responsible for identifying and reviewing opportunities for CSL’s global R&D pipeline. As a consequence Chris has extensive experience with both in-licensing and out-licensing therapeutic drugs and R&D enabling platforms. Earlier Chris spent three years as a postdoctoral scientist at The University of Cambridge, UK.
Chris is currently a director of; Aravax, Denteric, Ena Respiratory, MycRx, Okogen, Q-Sera and Axelia Oncology.
Chris has a Bachelor of Science (Honours) from The University of Melbourne, a PhD in Immunology conducted at the Walter and Eliza Hall Institute, and an MBA, specialising in innovation and entrepreneurship, from the University of Cambridge. Chris is a graduate of the Australian Institute of Company Directors.